Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. The drug, amycretin — developed by Novo Nordisk — works by replicating ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Equities in Canada's largest centre continued to make progress as Monday morning became afternoon, with resource stocks like ...